See every side of every news story
Published loading...Updated

Anova Announces First Patient Enrolled to Phase 1/2a Study of DB107 for the Treatment of High-Grade Gliomas - Pipelinereview

Summary by Pipelinereview
Anova is managing the delivery of Phase 1/2a study of DB107 at UCSF, USC, UCSD and with Denovo Biopharma DB107 is a proprietary gene therapy platform for the treatment of patients with newly diagnosed high-grade glioma Anova helped secure $11.8m CIRM funding to explore safety and efficacy of DB107 The first patient has enrolled following activation of UCSF, USC and UCSD in the study. LONDON, UK & CHICAGO, IL, USA I March 05, 2025 I Anova Enterpr…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pipelinereview broke the news in on Friday, March 7, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.